After a nearly 50% rally over the past year, Johnson & Johnson’s stock has cooled off in recent weeks. But with shares trading around $227, some analysts argue the healthcare giant remains undervalued — while others warn of lingering risks. We break down the bull and bear cases, with real investor reactions.
Fresh clinical results for Johnson & Johnson's recently approved TECNIS PureSee intraocular lens, presented at a major ophthalmology conference, are prompting a closer look at the healthcare giant's valuation as it sharpens its focus on high-growth medical device segments.
The healthcare giant's shares have significantly outperformed the broader market over the past year, yet Wall Street maintains a measured outlook amid regulatory and tariff pressures.
Johnson & Johnson announced promising 12-month pilot data for its OMNYPULSE Platform, reporting 100% acute procedural success with no device-related adverse events in treating symptomatic paroxysmal atrial fibrillation.
